Every open market buy and sale of Intellia Therapeutics, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are net sellers over the last 12 months: $1.4M bought and $2.3M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when NTLA insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an NTLA officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every NTLA insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | John M LeonardPresident and CEO | Sale plan | 9,000 | $11.99 | $108K | 1,138,064 | Nov 3Form 4 |
| Oct 2, 2026 | Michael P DubeVP, Chief Accounting Officer | Sale | 1,864 | $12.43 | $23K | 65,022 | Oct 6Form 4 |
| Aug 21, 2026 | John M LeonardPresident and CEO | Sale plan | 22,675 | $12.65 | $287K | 1,147,064 | Aug 24Form 4 |
| Jul 22, 2026 | Edward J Dulac IIIEvp, CFO | Sale | 8,111 | $11.25 | $91K | 148,175 | Jul 24Form 4 |
| Jul 2, 2026 | Edward J Dulac IIIEvp, CFO | Sale plan | 4,677 | $18.00 | $84K | 156,286 | Jul 6Form 4 |
| Jul 1, 2026 | Michael P DubeVP, Chief Accounting Officer | Sale | 2,641 | $16.78 | $44K | 66,886 | Jul 6Form 4 |
| Mar 2, 2026 | Eliana ClarkEVP, Chief Technical Officer | Sale | 607 | $13.78 | $8K | 93,864 | Mar 3Form 4 |
| Mar 2, 2026 | James BastaEVP, General Counsel | Sale | 1,211 | $13.78 | $17K | 156,794 | Mar 3Form 4 |
| Jan 5, 2026 | Fred E CohenDirector | Buy | 150,000 | $9.35 | $1.4M | 207,453 | Jan 7Form 4 |
| Jan 5, 2026 | Michael P DubeVP, Chief Accounting Officer | Sale | 2,989 | $9.21 | $28K | 52,277 | Jan 7Form 4 |
| Jan 5, 2026 | Edward J Dulac IIIEvp, CFO | Sale | 6,379 | $9.21 | $59K | 99,683 | Jan 7Form 4 |
| Jan 5, 2026 | Eliana ClarkEVP, Chief Technical Officer | Sale | 9,515 | $9.21 | $88K | 87,118 | Jan 7Form 4 |
| Jan 5, 2026 | David LebwohlEVP, Chief Medical Officer | Sale | 11,903 | $9.21 | $110K | 121,249 | Jan 7Form 4 |
| Jan 5, 2026 | James BastaEVP, General Counsel | Sale | 10,397 | $9.21 | $96K | 101,528 | Jan 7Form 4 |
| Jan 5, 2026 | Birgit C SchultesEVP, Chief Scientific Officer | Sale | 8,508 | $9.21 | $78K | 98,533 | Jan 7Form 4 |
NTLA insider trading FAQ
Are NTLA insiders buying or selling?
Insiders are net sellers over the last 12 months. 1 insiders bought $1.4M of NTLA on the open market in 1 trades, and 7 sold $2.3M in 16 trades, 58% of that under pre-arranged trading plans.
When did an NTLA insider last buy shares?
Fred E Cohen (Director) bought 150,000 shares for $1.4M on Jan 5, 2026, reported on Jan 7, 2026.
When did an NTLA insider last sell shares?
John M Leonard (President and CEO) sold 9,000 shares for $108K on Nov 2, 2026, under a pre-arranged trading plan.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
